Elucidation of new testing method in refractory multiple myeloma

2022 Fiscal Year Final Research Report

• Project/Area Number: 20K08746
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 54010:Hematology and medical oncology-related
• Research Institution: Asahikawa Medical College
• Principal Investigator: Shindo Motohiro 旭川医科大学, 医学部, 講師 (10396377)
• Project Period (FY): 2020-04-01 – 2023-03-31
• Keywords: 多発性骨髄腫

Outline of Final Research Achievements

Cell-free DNA (cfDNA) is an extracellular free DNA fragment that contains circulating tumor DNA (ctDNA). Recent studies have shown that cfDNA is useful for diagnosis and examining treatment efficacy in neoplastic disease. In this study, we investigated the genetic mutation of ctDNA in multiple myeloma patients and followed test results over time. From this study, we have found that the analysis of cfDNA is useful for monitoring disease status in patients with KRAS mutation. This finding suggests that cfDNA obtained from a blood test can be used to study disease status instead of bone marrow aspiration, which is more invasive.

Free Research Field

血液内科学

Academic Significance and Societal Importance of the Research Achievements

本研究では、侵襲の大きい骨髄穿刺検査に代わり、より侵襲の少ない血液検査による検体を用いることが特色である。血漿由来のcfDNAを用いた経時的解析が多発性骨髄腫の治療評価に有用である可能性が示された。